Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response

Biological Psychiatry

Volumn 46, Issue 1, 1999, Pages 73-77

  Conley, Robert R ^a   Tamminga, Carol A ^a   Kelly, Deanna L ^a   Richardson, Charles M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Clozapine; Olanzapine; Schizophrenia; Treatment resistance

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; MALE; PIRENZEPINE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032986659     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00029-3     Document Type: Article

References (26)

1. The APA steering committee expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry. 12b:1996;3-58.
2. Baldacchino A.M., Stubbs J.H., Nevinson-Andrews D. The use of olanzapine in noncompliant or treatment-resistant clozapine populations in hospitals. Pharm J. 260:1998;207-209.
3. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia a randomized double-blind study. The risperidone study group . Am J Psychiatry. 155:1998;499-504.
4. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., Carpenter W.T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 155:1998;751-760.
5. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan W., et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 13:1993;25-39.
6. Clozapine package insert, Novartis Pharmaceuticals Corporation, October 1997.
7. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. 1988;Lawrence Erlbaum Associates, Hillside, NJ.
8. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 23:1997;663-674.
9. Conley R.R., Carpenter W.T., Tamminga C.A. Time to clozapine response in a standardized trial. Am J Psychiatry. 154:1997;1243-1247.
10. Conley R.R., Tamminga C.A., Bartko J., Richardson C., Peszke M., Lingle J., et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 155:1998;914-920.
11. DeRenzo E.G., Conley R.R., Love R.C. Assessment of capacity to give consent to research participation state-of-the-art and beyond . J Health Care Law Policy. 1:1998;66-87.
12. Ekblom B., Haggstrom J.E. Clozapine (Leponex) compared with chlorpromazine a double-blind evaluation of pharmacological and clinical properties . Curr Ther Res Clin Exp. 16:1974;945-957.
13. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry. 45:1988;789-796.
14. Klieser E., Lehmann E., Kinzler E., Wurthmann C., Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol. 15:(suppl 1):1995;45S-51S.
15. Marder S.R., Meiback R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1:1994;825-835.
16. Martin J., Gomez J.C., Garcia-Bernardo E., Cuesta M., Alvarez E., Gurpegui M., et al. Olanzapine in treatment-refractory schizophrenia results of an open-label study . J Clin Psychiatry. 58:1997;479-483.
17. Meltzer H.Y., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia impact on risk-benefit assessment . Am J Psychiatry. 152:1995;183-190.
18. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., Rapaport M.H. Clinical and biological response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry. 49:1992;345-353.
19. Ranjan R., Meltzer H.Y. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry. 40:1996;253-258.
20. Shore D. Clinical implications of clozapine discontinuation report of an NIMH workshop . Schizophr Bull. 21:1995;333-337.
21. Simpson G.M., Varga E. Clozapine-a new antipsychotic agent. Curr Ther Res Clin Exp. 16:1974;679-686.
22. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders results of an international collaborative trial . Am J Psychiatry. 154:1997;457-465.
23. Tollefson G.D., Beasley C.M., Tamura R.N., Tran P.V., Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 154:1997;1248-1254.
24. Tollefson G.D., Sanger T.M., Lu Y., Thieme M.E. Depressive signs and symptoms in schizophrenia a prospective blinded trial of olanzapine and haloperidol . Arch Gen Psychiatry. 55:1998;250-258.
25. Tran P.V., Dellva M.A., Tollefson G.D., Beasley C.M., Potvin J.H., Kliesler G.M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 58:1997;205-211.
26. Weisler R.H., Ahearn E.P., Davidson J.R., Wallace C.D. Adjunctive use of olanzapine in mood disorders five case reports . Ann Clin Psychiatry. 9:1997;259-262.